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Abstract
Preterm birth is the leading cause of neonatal mortality and perinatal morbidity. The etiology of preterm is multi-
factorial and still unclear. As evidence increases for a genetic contribution to PTB, so does the need to explore
genomics, transcriptomics, proteomics and metabolomics in its study. This review suggests research guidelines for
the conduct of high throughput systems biology investigations into preterm birth with the expectation that this
will facilitate the sharing of samples and data internationally through consortia, generating the power needed to
study preterm birth using integrated “-omics” technologies. The issues to be addressed include: (1) integrated
“-omics” approaches, (2) phenotyping, (3) sample collection, (4) data management-integrative databases, (5)
international consortia and (6) translational feasibility. This manuscript is the product of discussions initiated by the
“-Omics” Working Group at the Preterm Birth International Collaborative Meeting held at the World Health
Organization, Geneva, Switzerland in April 2009.
Preterm birth, (PTB - birth before 37 weeks gestation),
is the leading cause of neonatal mortality and is asso-
ciated with up to 75% of long-term morbidity including
developmental delay, cerebral palsy, retinopathy of pre-
maturity, and hearing and vision problems [1,2]. Despite
medical advances and better understanding of uterine
activation and parturition, the rates of PTB have been
increasing over the past three decades in developed
countries [3]. with current rates ranging from 5-7% [4].
and also complicate 9.6% of all births worldwide [5].
Late PTBs, defined as delivery at 34
+0 weeks to 36
+6
weeks of pregnancy [6], have risen 25% since 1990, [7].
now accounting for three quarters of preterm deliveries.
This stark increase may be attributed to fetal indica-
tions, preterm premature rupture of membranes
(PPROM) and its associated risks, and the increase in
multiple pregnancies associated with assisted reproduc-
tive technology [8]
Complicating our understanding of PTB is that it’s
etiology is multifactorial and varies by gestational age.
Among factors associated with increased risk of PTB are
maternal smoking during pregnancy, [9,10] advanced
maternal age, [11,12] sub-optimal weight gain during
pregnancy, [13] maternal stress, [14-16] decidual throm-
bosis [17], cervical insufficiency [18,19] and the presence
of infection [20-22]. In addition, a variety of environ-
mental and genetic play a role in PTB; however the
effect size of these factors is not clear. In the United
States, PTB occurs disproportionately in women of Afri-
c a na n c e s t r y[ 2 3 , 2 4 ]e v e nw h e nc o n t r o l l i n gf o rs o c i a l
confounders. Twin studies suggest that the heritability
of PTB may be 17-36% [25,26]. Clinically, the best pre-
dictor of PTB is a prior history, [27,28]. where recur-
rence risk increases by approximately 15% with each
PTB [29]. Further, data suggest that the risk of PTB is
inherited across generations [30]. As evidence increases
for a genetic contribution to PTB, so does the need to
explore genomics, transcriptomics, proteomics and
metabolomics in its study.
High throughput systems biology, referred to as
“-omics” technology has revolutionized research
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ogies and the generation of massive data sets, it is now
possible to do in an afternoon what previously took sev-
eral years and yet our understanding of the complex
phenotypes of PTB remain incomplete, inconsistent and
without clinical clarity. The “-omics” era has seen many
publications (> 250, 000) however only a limited number
(~6, 000) have been in reproductive medicine (Figure 1).
Many of the “-omics” publications relating to PTB have
assessed single classes of “-omics” data, utilizing geno-
mics, transcriptomics or proteomics in isolation. The
r e s u l t so fm a n yo ft h e s e“-omics” publications have
failed to replicate and their practical value has been lim-
ited, failing to translate into clinical practice. The lim-
ited successes of singular approaches emphasize the
need for integrated approaches to investigate complex
phenotypes across “-omics” categories.
To support both singular and integrated systems biol-
ogy approaches, the “-omics”, or systems biology, move-
ment has seen the development of multiple consortiums
utilizing high throughput platforms to investigate com-
plex phenotypes. Central to the study of complex phe-
notypes are accurate phenotype definitions. In the study
of PTB, this necessitates collaboration among multiple
research groups working synergistically to define pheno-
types and to provide adequate sample size [31]Consor-
tia, by design, employ multiple sites for the collection of
phenotype data and biological samples with the goal of
creating sample sizes large enough to power studies at
levels impossible for any single research group, institute
or funding opportunity. Moreover, “-omics” technologies
require high quality biologic samples with specific, con-
sistent and precise collection and handling. Key to effec-
tive consortia is consistency in information gathered,
specimen collection, storage and management without
which merging of data is problematic.
There is a need for guidelines for the conduct of inte-
grated “-omics” s t u d i e si n t oP T B .T h eg e n o m i c ,t r a n -
scriptomic and proteomic working group from the
Preterm Birth International Collaborative (PREBIC)
meeting in 2009 propose these suggested guidelines.
The aim of this article is to establish guidelines for
“-omics” studies of PTB such that data and samples col-
lected can be merged, compared and replicated through
consortia capable of integrated systems biology meth-
odologies. The issues to be addressed in this guideline
include: (1) integrated “-omics” approaches, (2) pheno-
typing, (3) sample collection, (4) data management-inte-
grative databases, (5) international consortia and (6)
translational feasibility.
Integrated “-omics” Systems Biology Approaches
Until recently the “-omics” era consisted of studies in
genomics (the study of genes and their functions), tran-
scriptomics (the study of the complete set of RNA tran-
scripts produced by the genome at one time), and
proteomics (the study of the complete set of proteins
produced by a species). Recently, through the develop-
ment of new technologies, metabolomics (the study of
small-molecule metabolite profiles generated by cellular
Figure 1 Systems Biology “-Omics” Publications in Relation to Pregnancy. Published articles utilizing selected systems biology approaches
from 1999-2010. Those related to pregnancy generally less than 3% (note log scale) of the total published articles, and have only begun to
increase in 2009. Data abstracted from PubMed with search terms: Human AND English + [transcriptome OR transcriptomics, transcriptome OR
transcriptomics + pregnancy, proteome OR proteomics, proteome OR proteomics + pregnancy, genome OR genomics, genome OR genomics +
pregnancy, metabolome OR metabolomics, and metabolome OR metabolomics + pregnancy].
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considerations for using each “-omics” platform in stu-
dies of PTB and its sequelae have been reviewed else-
where [32]. Additionally, the limitations of investigations
using “-omics” in isolation have been discussed [33] and
emphasize the need for integrated “-omics” approaches
as the future path of research.
A step-wise integrated approach is central “-omics”,
yet without strategic implementation, integrating
“-omics” fields may be plagued by limitations compar-
able to the utilization of singular approaches. Each step,
or technique, yields distinctly different information (Fig-
ure 2) in discovery research. Transcriptomics, not in iso-
lation but rather as an entry point for investigation,
presents unique advantages for the study of PTB and
perhaps other complex phenotypes alike. Unlike geno-
mics, transcriptomics provides a snapshot of what
appears to be happening at a given point in time in a
biological sample. Therefore, if patterns are observed
which are specific to PTB phenotypes, the functional
consequences (protein products) or genetic predisposi-
tion (single nucleotide polymorphisms - SNPs) may be
ascertained and feedback interactions and processes
explored. Proteomics and metabolomics are also promis-
ing techniques as analytic steps essential to integrated
discovery research studies. These steps are able to build
upon the patterns revealed by transcriptomics, as tran-
scriptomes are putative precursors to the actual
physiology. However, sample processing requirements
and still rapidly evolving technologies pose special chal-
lenges in the use of proteomics and metabolomics, as
opposed to candidate driven research. In comparison,
genomics is limited by the lack of linear associations
between genetic variants and complex phenotypes (Fig-
ure 3). It holds its intrinsic value in secondary analyses
and should also be including in integrated investigations.
Utilizing multiple complimentary techniques strategi-
cally in integrated studies may reveal the pathophysiolo-
gical insights and clinical clarity PTB research seeks to
discover.
The Phenotype of Preterm Birth
The World Health Organization defines PTB as “birth
before 37 weeks (or 259 days) gestation”[34]. Preterm
birth is therefore unique among adverse pregnancy out-
comes in that it is defined by a time point and not be
specific etiology or pathophysiology. However, as an
obstetric syndrome, PTB represents a common end
point to a wide variety of clinical conditions that have
been classified inconsistently in a number of ways that
have included: 1) gestational age at which delivery
occurs; 2) clinical presentation resulting in PTB; and 3)
putative pathophysiology responsible for PTB. These
classification systems are not mutually exclusive, with
each of them offering different benefits depending on
the scientific or clinical question of interest, but
Figure 2 Systems Biology Tools for Reproductive Medicine. The main systems biology categories vary in size and physiological information
generated from their study. Together, a more complete understanding of PTB pathophysiology can be ascertained. Adapted from [Dettmer K,
Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 2007;26:51-78.]
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the PTB phenotype within the study population.
The most common classification system for PTB is
based on gestational age at delivery where cases are clas-
sified into strata of extreme prematurity (< 28 weeks
gestation), severe prematurity (28-31 weeks gestation),
moderate prematurity (32-33 weeks gestation) and near
term prematurity (34-37 weeks gestation)[3]. The major-
ity of PTB occurs between 34 and 37 weeks gestation
with smaller numbers occurring at lower gestational
ages [35]. Unfortunately, accurate assessment of gesta-
tional age is not always possible, especially in low and
middle-income settings where the burden of disease is
high, and resources limited. The last menstrual period is
frequently unknown, early dating ultrasound unavailable,
and where most births occur home. The need for better
tools to accurately assess gestational age is therefore a
key research imperative to facilitate “omics” biology in
PTB.
Until such tools are available, alternative classification
based upon clinical presentation or proposed pathophy-
siology are more likely to be of value in understanding
the genetic and physiological processes that lead to PTB.
In clinical classification schemes, after excluding
multi-fetal pregnancy, severe fetal malformations and
fetal death in-utero, PTB can be broadly classified into
two clinical pathways - iatrogenic PTB and spontaneous
PTB (Figure 4).
Figure 3 A General Model of “-Omics” in Complex Disease. Variation in the genome is represented in the transcriptome which is presented
in the proteome. Each level is represented by an oval. For the genome each dot in the oval is a different gene or sequence variant. These
variants are expressed as part of the transcriptome. However, unlike the genome which is essentially invariant among cells and tissues the
transcriptome can differ substantially. Different tissues are represented by overlapping ovals. Similarly, the transcriptome is translated into the
proteome differently in different tissues (again represented as overlapping ovals). The proteome affects the metabolome in a tissue specific
manner and the latter two sultimately influence the phenotype. This simple model is modified by multiple factors within and among levels
noted on the figure as: A) Differential splicing that can be affected by the proteome; B) siRNA and/or micro RNA; C) post-translation modification
of proteins; D) transcription factor binding; E) receptor ligand binding; F) environmentally induced factors such as epigenetic modifications,
mutagenesis or modifier of gene expression.
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occurs when the benefits to either the mother or fetus
of delivery outweigh the benefits of continuing preg-
nancy. Iatrogenic PTB occurs in about 25% of all PTB
with variations from 8.7% to 35.2% according to studied
populations [36]. This clinical phenotype includes pree-
clampsia, diabetes, other maternal medical conditions
and fetal growth restriction, a range of conditions with
differing etiologies, risk factors and clinical outcomes.
As a result of an increased ability to monitor fetal health
during pregnancy and recognize the onset of maternal
disease earlier, iatrogenic PTB is becoming more com-
mon and the increasing rate of late PTB is thought to
be largely attributable to iatrogenic causes [3]
Spontaneous preterm birth can result from either
spontaneous preterm labor (defined as regular contrac-
tions with cervical changes at less than 37 weeks gesta-
tion) or preterm pre-labor rupture of membranes
(PPROM) defined as spontaneous rupture of the
membranes at least 1 hour before the onset of labor and
at less than 37 weeks gestation [37]. SPTB accounts for
approximately 50% of all PTB (range 23.2% to 64.1%)
[36,38]. It is more frequent in populations without any
established risk factors in which it represents 50% to
70% of all preterm deliveries [39,40]
It is important to recognize that classifications of PTB
based on clinical presentation or gestational age at deliv-
ery result in different study groups as the proportion of
PTB that are iatrogenic and spontaneous varies between
study populations, [41-46] racial backgrounds [41-46]
and gestational age [41,47]. Regardless, it is likely that
the ultimate pathophysiological mechanisms and path-
ways involved in PTB are similar across groups.
It has been hypothesized that PTB and term birth
share similar final physiological pathways, but that these
pathway are triggered early in PTB [48]. This common
pathway of parturition involves the activation of various
physiological processes including myometrial
Figure 4 The Phenotypic Distribution of Preterm Birth. After excluding multifetal pregnancy and severe fetal malformations/fetal death in-
utero, PTB can be classified into two broad clinical pathways - iatrogenic PTB and spontaneous PTB Adapted from Morken NH, Kallen K,
Hagberg H, Jacobsson B. Preterm birth in Sweden 1973-2001: rate, subgroups, and effect of changing patterns in multiple births, maternal age
and smoking. Acta Obstet Gynecol Scand. 2005;84:558-65 and PENNELL CE, JACOBSSON B, WILLIAMS SM, et al. Genetic epidemiologic studies of
preterm birth: guidelines for research. Am J Obstet Gynecol 2007;196:107-18.
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matrix degradation, weakening and rupture and cervical
ripening resulting in labor and delivery [37,48]. While
the physiological triggers of this final pathway in term
birth are still not well understood, the proposed patho-
logical triggers that have been proposed for PTB are
outlined in Figure 5. Activation of one (or more) of
these triggers and their interaction with environmental
factors and genetic susceptibility in the host can lead to
activation of the common parturition pathway at an ear-
lier gestational age and result in PTB.
This complexity is often disregarded in “-omics”
research into PTB where spontaneous PTB, preterm
premature rupture of membranes, and even iatrogenic
PTB are commonly grouped together for analyses. The
heterogeneity resulting from grouping known clinical
presentations together decreases the sensitivity and
power of many research studies. It is vital that PTB is
distinguished by its different phenotypes prior to all
analyses, including those utilizing “-omics” technologies.
Although this may decrease numbers in any given study,
it may increase biological homogeneity, thereby poten-
tially replacing the lost statistical power.
Sample Collection and Processing
Sample collection for “-omics” research is not without
it’s own considerations, complications and detailed pro-
tocols. For PTB research, the biological sample collected
is determined by the research question of interest; there-
f o r eaw i d ev a r i e t yo ff l u i d sor tissues such as cervical
mucus, blood, urine, saliva, vaginal discharge, myome-
trium, and uterine tissues are appropriate depending on
the investigation. Collection of these specimens should
be carefully planned a priori and the consistency of
handling closely monitored to assure specimens are
representative of the physiology rather than a reflection
of ex vivo handling. To ensure samples are of maximum
utility to individual and consortia investigations,
extracted DNA, RNA, proteins or metabolites should be
handled consistently. Table 1 provides an outline of
approaches that can be utilized. The availability of biolo-
gical specimens by itself is not sufficient for integrated
Figure 5 Proposed Pathophysiological Pathways Leading to Preterm Birth. The pathophysiology of preterm birth is innately complex and
incompletely understood. Several genetic, physiological and environmental factors are associated with preterm birth and contribute to uterine
activation, labour and ultimately birth.
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mentation of the phenotypes is, as noted above, essen-
tial. Regardless of the classification system for PTB
employed (Section 2), each sample should have the
minimal dataset available (Table 2[41]) and if possible,
the optimal dataset (Table 3[41]) described originally for
genetic epidemiology studies of PTB but which translate
directly into integrated “-omics” approaches in general.
4. Data Managements - Integrative Databases
A major limitation to current progress in understanding
the genetic predispositions to PTB is that only a limited
number of genetic epidemiologic studies are available
representing various ethnic/racial groups globally [49].
Therefore, there is a critical need for large and compre-
hensive clinical resources linked to biospecimen banks.
At the level of individual investigators or small teams of
researchers, clinical, environmental and biological data
are continually being collected for studies with relatively
small sample sizes. While it is possible to obtain high
quality, mergeable data on large numbers of high-risk
pregnancies, the use of this approach is limited (in part)
by the absence of field standards and guidelines. With-
out these navigational beacons, the current use of inade-
quately sized cohorts or samples has resulted in
inconsistent and possibly spurious initial findings for
“-omics” results in PTB studies. This is likely due to the
multi-genic/multifactorial origin of PTB where any
given factor/gene may contribute at most a few percent
to the phenotypic variation.
If consistency is present in sample and data collection,
an integrated international dataset becomes possible and
transparent. The creation of integrated databases that
contain both clinical (phenotype) data and biospecimen
data has two additional major benefits: access and disse-
mination. This will allow researchers across the globe to
work synergistically to attempt to answer many of the
unanswered questions about PTB utilizing adequate
sample sizes and the latest developments in technology.
Robust technology and analytical infrastructure is
imperative to support the vast amounts of data
generated.
Table 1 Sample processing for “-omics” studies of preterm birth
“-omics”
Platform
Appropriate
Samples
Special Considerations
Genomics (DNA) Blood
Saliva
Stable at room temperature but best if refrigerated
Salivette superior to buccal swab for high through-put genotyping
Transcriptomics
(RNA)
Blood
Amniotic fluid
Cervico-vaginal
fluid
Myometrium
Amnion
Chorion
Decidua
All samples require appropriate collection equipment, meticulous processing and sample storage to insure
integrity of RNA for analysis
Proteomics
(protein)
Plasma
Amniotic fluid
Cervico-vaginal
fluid
Myometrium
Amnion
Chorion
Decidua
Urine
All samples require rapid preparation and preservation (+/- protease inhibitors) to prevent non-specific
protein degradation
Metabolomics Blood
Amniotic fluid
Urine
Samples require rapid metabolic “quenching” (e.g., flash freezing or acid precipitation) to prevent degradation
of metabolome
Suggested biological samples and sample handling considerations for each stream of “-omics” technology for the study of preterm birth. The optimal sample to
collect should be determined by the driving research question for each investigation.
Table 2 The PREBIC Minimal Dataset for “-Omics” Studies
on Preterm Birth
Minimal Dataset
￿ Spontaneous initiation vs. Medically indicated preterm birth
￿ Living fetus vs. intrauterine death at labor initiation
￿ Singleton vs. multi-fetal gestation
￿ Gestational age at delivery
￿ Environmental exposures (tobacco, ethanol, recreational drugs)
￿ Maternal age
￿ Parity
￿ Past obstetrical history
￿ Ethnicity
The minimal dataset required for international merging of biological samples
for “-omics” studies on preterm birth. Adapted from PENNELL CE, JACOBSSON
B, WILLIAMS SM, et al. Genetic epidemiologic studies of preterm birth:
guidelines for research. Am J Obstet Gynecol 2007;196:107-18.
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PTB is a global problem with increasing rates in devel-
oped countries yet the vast majority of cases occur in
the developing world (Table 4) [5]. International consor-
tia are therefore needed to bring together resources,
experts and data from low, middle and high-income
countries to facilitate “-omics” research of PTB and to
disseminate results to all who may benefit.
An integrated “-omics” approach for PTB holds the
potential for enormous scientific and, ultimately, clinical
benefit. The ultimate goal of such research is the
improvement of biological understanding leading to pre-
vention, early diagnosis tools, and treatment for PTB
and its associated outcomes.
There are currently consortia established to investigate
genome wide associations with PTB. All of these con-
sortia are limited in their sample sizes due to the costs
of genotyping and it is likely that meta-analyses of these
data will be required to make substantial advances in
our understanding of the genetic contributions of PTB.
Most international consortia have an organized struc-
ture including an executive that contains both consortia
leadership and members from each of the individual stu-
dies or data collection sites contributing data to the
consortia. Detailed memorandums of agreement are
required between both participating universities and
researchers to facilitate smooth working of these
consortia.
One example is the Preterm Birth Genome Project, a
global consortium to study genetic predisposition in
PTB. This consortium includes investigators not only
from industrialized nations but also from low and mid-
dle-income countries in South America, Eastern Europe,
Asia and Africa. The Preterm Birth Genome Project
(PGP) was initiated within PREBIC members in Septem-
ber 2007. This consortium includes investigators from
four continents and has established a memorandum of
agreement to collaborate on GWAS by pooling
resources (DNA) and establishing a database of pheno-
type definitions. The goals of the PGP consortium have
been to 1) create a community of researchers to identify
PTB susceptibility genes; 2) pool resources from multi-
ple investigators to conduct GWAS across multiple geo-
graphic populations including detailed phenotypic and
environmental data; 3) to establish a large pool of repli-
cation samples; and 4) to enable deep re-sequencing of
genes with significant and/or interesting findings in
GWAS. This consortium has been highly successful in
both collecting resources (> 5000 cases, > 5000 controls)
and also funding research into this rapidly evolving field.
A recent consortium is established by PREBIC bio-
marker working based on a systematic review of SPTB
biomarker literature published between 1965-2008. Due
to heterogeneities in study designs including above
detailed issues of study designs, phenotype definitions
Table 3 Additional Information Desirable for Optimal Dataset for “-Omics” Studies on Preterm Birth
Optimal Dataset
￿ Demographic
○ Socioeconomic status, maternal education
￿ Clinical
○ Spontaneous onset vs. induced labor
￿ Maternal
○ Body mass index (BMI), nutritional status, weight gain, uterine anomaly, psychological stress, medications, uterine or cervical surgery, mode of
conception, infection, pre-existing medical conditions, pregnancy complications
￿ Fetal
○ Birth weight, anomalies, infection
￿ Placental histopathology
￿ Family history
○ History of preterm birth, maternal gestational age at delivery
The optimal dataset suggested for international merging of biological samples for “-omics” studies on preterm birth. Adapted from PENNELL CE, JACOBSSON B,
WILLIAMS SM, et al. Genetic epidemiologic studies of preterm birth: guidelines for research. Am J Obstet Gynecol 2007;196:107-18.
Table 4 Regional Variation in Preterm Birth Rates
Region Preterm Births Preterm Birth Rate (%)
World Total 12, 870, 000 9.6
By Economic Development
Developed Regions 1, 014, 000 7.5
Less Developed Regions 7, 685, 000 8.8
Least Developed Regions 4, 171, 000 12.5
By Region
Africa 4, 047, 000 11.9
Asia 6, 907, 000 9.1
Latin America 933, 000 8.1
North America 480, 000 10.6
Europe 466, 000 6.2
Oceania
(Australia/New Zealand)
20, 000 6.4
The global burden of preterm birth varies by region with the highest rates
occurring in developing regions. Adapted from BECK S, WOJDYLA D, SAY L, et
al. The worldwide incidence of preterm birth: a systematic review of maternal
mortality and morbidity. Bull World Health Organ;88:31-8.
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biomarker emerged as a risk predictor. Preterm Birth
Biomarker Project (PBP) is setup to address these issues.
This study will identify homogeneous studies/samples
from around the globe to be tested on a panel of poten-
tial PTB biomarkers.
Similarly, further consortia will be required to utilize
“-omics” technology and a systems biology approach to
study PTB; however, those in existence rarely have ade-
quate samples amenable to multiple “-omics” analyses.
We hope that this paper will motivate others to increase
the variety of biological samples collected to better
address the major hurdles to the study of PTB.
Translational Feasibility - Barriers and Constraints
Despite the increasing number of publications docu-
menting the utilization of “-omics” technologies for PTB
prediction or preterm labor diagnosis, translation into
clinical utility is absent despite its continued promise.
This apparent gap in knowledge translation reveals both
barriers and constraints to applying insights gained from
“-omics” investigations of complex diseases. The incon-
sistencies in defining PTB phenotypes, sample handling
methods and environmental variables have, not surpris-
ingly, made reproducibility of study findings nearly
impossible. These mixed messages plague the PTB lit-
erature and limit the interpretation of “-omics” gener-
ated knowledge, hindering translational feasibility. This
is of course not unique to PTB.
Genomic analyses of complex traits such as PTB
implicitly and explicitly make assumptions regarding the
nature of the risks conferred by genetic variants. The
most important of these assumptions is that variants in
the nucleotide level are linear (or nearly so) in terms of
their effects on disease risk. Therefore, one can test for
associations between single nucleotide polymorphisms
(SNPs) and PTB with the expectation that the role of
any given change is transparent to intermediate pro-
cesses that are included in the central dogma of molecu-
lar biology and its correlates (DNA to RNA to protein;
Figure 2). Specifically, a gene is transcribed and the
mRNA translated in such a way that changes in base
pair composition in a gene encoding a critical protein
are easily detectable at the phenotypic level. Although
this is a very powerful model and in general approxi-
mately true (especially for Mendelian disorders), recent
research has indicated that this unidirectional process is
not universal and many non-linear processes are part of
the progression (Figure 4). The failure of the linear
model has many implications for the genetic/genomic
analyses of PTB. Foremost is the fact that any changes
in the primary DNA sequences are not necessarily
directly or easily translated into phenotypic changes.
Instead, a large number of intermediate processes
modulate the effects of DNA variation. Therefore,
changes in the DNA may be difficult to detect using a
simple association methodology even though they play a
key role in disease etiologies. The goal therefore is to
more completely model the overall process of gene to
phenotype. As a field, we need to recognize that this
approach in time will lead to clinical advances to better
predict disease and to the design of more effective pre-
ventative strategies and treatment. While it is universally
accepted that translation is the goal, this is not a realis-
tic deliverable or tangible aim of any single investigation
or approach, although this is often implicitly promised.
The now clear need to link data sets from multiple
studies is pivotal to the progress of PTB research. How-
ever, the goal of integrated international consortia using
“-omics” generated data will further complicate transla-
tional feasibility if ethical considerations are not
addressed proactively at the individual study and con-
sortia levels. When conducting integrated “-omics”
investigations ethics boards, participants and researchers
face new challenges beyond that of the complexity of
the huge data sets produced. The most significant of
these include: (1) ensuring robust informed consent and
community engagement, (2) dissemination or sharing of
research results or other benefits, and (3) sensitivity to
the special concerns of participants, typically, pregnant
women.
First, consortia will need to address a reoccurring ques-
tion “how can robust informed consent be sought from
participants?”[50-52]. Because the details of future joint
ventures are often unknown or impossible to anticipate,
obtaining robust informed consent from participants at
the time of enrolment to share samples with international
consortia is difficult. Similarly, ethics committees face
challenges during review, as they cannot evaluate each
unanticipated use of data. Participants themselves may be
hesitant to partake in studies when the destiny of their
samples and information is unknown. The de-identifica-
tion of biological samples and clinical information is
designed to protect the confidentiality of individual parti-
cipants. However, exactly what information collected by
the original study team would be required by a secondary
investigator to merge datasets? This may result in only
the partial de-identification of participants. Therefore
each study design must consider and clarify during the
process of informed consent whether consent to share
information internationally is optional or required for
participation, a choice which may introduce participant
bias into study populations. Furthermore, when samples
and data are shared internationally, it becomes unclear
who bears the onus to maintain the security of the inte-
grated databases and storage of specimens. The security
of internationally shared information raises significant
ethical and legal considerations.
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research findings. Linking and integrating large data sets
and their associated biospecimen banks is not inherently
straightforward, nor is the dissemination of knowledge
generated back to the original communities. These ethi-
cal challenges are not unique to PTB research but rather
impact biobanking and international consortia efforts in
all fields; as such models and lessons developed in rela-
tion to cancer research, for example, may be tailored to
PTB research. In regards to participants, consortia com-
prised of representatives from each of the contributing
data pools may facilitate the dissemination of study
results to their respective participants while still main-
taining subject privacy at the consortia level. This would
also enable the channeling of information to the original
investigators and local communities whom supported
the primary data and sample collection. The obligation
to return consortia generated results to participants will
depend upon the scope and duration of the relationship
between the consortia, investigators and participants
and therefore may not be possible in all cases. Sharing
aggregate consortia generated results may be facilitated
by password-protected web-based research updates and
newsletters, to keep project level investigators and parti-
cipants aware of ongoing aggregate findings. These can
include contact information for participants and
researchers with questions about the studies and aggre-
gate findings. Such sites can also serve as a place for
posting educational information about healthy pregnan-
cies, child development or parenting strategies. Because
of the psychological burden that attends PTB for
women and parents globally, international consortia may
be in a position to facilitate social networking among
participants or communities by allowing voluntary anon-
ymous participant-participant communication through
these websites. This is a way to engage participants in
long-term studies and to provide benefit, when signifi-
cant clinical findings (and therefore direct benefit) for
individual participants are not expected.
Third, PTB research also needs to consider the speci-
fic expectations and experience of participants [53].
Women or couples who have suffered through one or
more preterm births, pregnant women who have experi-
enced a prior preterm or stillbirth, or have a family his-
tory of PTB, will likely experience heightened anxiety
about their pregnancy that should be taken into consid-
eration during the recruitment process [53]. Similarly,
such women may have an expectation that by participat-
ing in research, they will “find a cure” to prevent pre-
term delivery in this pregnancy or a subsequent
pregnancy [54]. Attention to these sensitive issues
should shape the informed consent process and be con-
sidered by consortia utilizing data and specimens col-
lected from these women. As integrated datasets come
to the forefront of PTB research, the investments and
interests of the participants, local investigators, local
communities and international research communities
cannot be forgotten. International consortia may be
positioned to best preserve these interests by facilitating
shared ethical practices rather than leaving each investi-
gator or institution to wrestle with these issues on their
own.
Conclusion
The “-omic"s era presents an exciting time for PTB
research. Opportunities now exist to address complex
biology utilizing technology that can achieve in a matter
of hours what once took many years if possible at all.
Although the “-omics” revolution has promise, there are
important limitations and constraints to these
approaches that cannot go unnoticed. Critical needs at
the current time include: 1) improved phenotyping for
PTB; 2) large and well-characterized case and control
samples with DNA; 3) one or more genome-wide asso-
ciation studies for PTB with broad replication across dif-
ferent populations; and 4) an international consortium
for PTB “-omics”. Only through the use of multicenter
collaborations, careful, detailed phenotyping, specific
and consistent sample collections, integrated systems
biology approaches and the shedding of simplistic
assumptions of the gene-to-phenotype cascade will
“-omics” technologies be able to provide new insights
into the complex pathophysiology of PTB. The possibili-
ties are within reach and consortia may offer the answer
to data management. These guidelines for research pro-
vide the direction necessary to harness the promises of
“-omics” technologies for advances in the understanding,
treatment and prevention of PTB.
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